Is the future of statins aligned with new novel lipid modulation therapies? (Q38073148)

28 August 2017

1 reference

title

Is the future of statins aligned with new novel lipid modulation therapies? (English)

1 reference

28 August 2017

2

Peter P Toth

1 reference

28 August 2017

Binh An P Phan

1

1 reference

28 August 2017

1 February 2013

1 reference

Current Atherosclerosis Reports

28 August 2017

1 reference

28 August 2017

15

1 reference

28 August 2017

2

1 reference

28 August 2017

300

1 reference

https://scigraph.springernature.com/pub.10.1007/s11883-012-0300-x

28 August 2017

0 references

cites work

Heart disease and stroke statistics--2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee

1 reference

https://api.crossref.org/works/10.1007%2FS11883-012-0300-X

Simultaneous low-density lipoprotein-C lowering and high-density lipoprotein-C elevation for optimum cardiovascular disease prevention with various drug classes, and their combinations: a meta-analysis of 23 randomized lipid trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-012-0300-X

Cholesterol in the prediction of atherosclerotic disease. New perspectives based on the Framingham study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-012-0300-X

The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-012-0300-X

Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-012-0300-X

MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-012-0300-X

Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-012-0300-X

Intensive versus moderate lipid lowering with statins after acute coronary syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-012-0300-X

Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-012-0300-X

Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-012-0300-X

Clinical characterization and molecular mechanisms of statin myopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-012-0300-X

Understanding Statin Use in America and Gaps in Patient Education (USAGE): an internet-based survey of 10,138 current and former statin users.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-012-0300-X

Efficacy and safety of rosuvastatin therapy for children with familial hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-012-0300-X

Mechanisms of disease: genetic causes of familial hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-012-0300-X

PCSK9: a convertase that coordinates LDL catabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-012-0300-X

Molecular biology of PCSK9: its role in LDL metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-012-0300-X

Multiple rare variants in NPC1L1 associated with reduced sterol absorption and plasma low-density lipoprotein levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-012-0300-X

Adenoviral-mediated expression of Pcsk9 in mice results in a low-density lipoprotein receptor knockout phenotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-012-0300-X

Antisense inhibition of proprotein convertase subtilisin/kexin type 9 reduces serum LDL in hyperlipidemic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-012-0300-X

Sequence variations in PCSK9, low LDL, and protection against coronary heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-012-0300-X

Atorvastatin increases human serum levels of proprotein convertase subtilisin/kexin type 9.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-012-0300-X

New lipid-lowering drugs: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-012-0300-X

Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised con

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-012-0300-X

Familial hypobetalipoproteinemia: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-012-0300-X

Recent progress in understanding apolipoprotein B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-012-0300-X

Differential response of cholesterol and particle measures of atherogenic lipoproteins to LDL-lowering therapy: implications for clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-012-0300-X

Why is non-high-density lipoprotein cholesterol a better marker of the risk of vascular disease than low-density lipoprotein cholesterol?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-012-0300-X

Antisense therapy and emerging applications for the management of dyslipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-012-0300-X

Effect of mipomersen, an apolipoprotein B synthesis inhibitor, on low-density lipoprotein cholesterol in patients with familial hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-012-0300-X

Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-012-0300-X

MTP inhibition as a treatment for dyslipidaemias: time to deliver or empty promises?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-012-0300-X

Absence of microsomal triglyceride transfer protein in individuals with abetalipoproteinemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-012-0300-X

Analysis of the role of microsomal triglyceride transfer protein in the liver of tissue-specific knockout mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-012-0300-X

New lipid modulating drugs: the role of microsomal transport protein inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-012-0300-X

Inhibition of microsomal triglyceride transfer protein in familial hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-012-0300-X

Inhibition of microsomal triglyceride transfer protein alone or with ezetimibe in patients with moderate hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-012-0300-X

The effect of thyroid disorders on lipid levels and metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-012-0300-X

Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-012-0300-X

Thyroid mimetic as an option for lowering low-density lipoprotein

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-012-0300-X

Effects of triiodothyronine and amiodarone on the promoter of the human LDL receptor gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-012-0300-X

The liver-selective thyromimetic T-0681 influences reverse cholesterol transport and atherosclerosis development in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-012-0300-X

Selective thyroid hormone receptor-beta activation: a strategy for reduction of weight, cholesterol, and lipoprotein (a) with reduced cardiovascular liability

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-012-0300-X

Effects of the thyroid hormone receptor agonist GC-1 on metabolic rate and cholesterol in rats and primates: selective actions relative to 3,5,3'-triiodo-L-thyronine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-012-0300-X

The thyroid hormone mimetic compound KB2115 lowers plasma LDL cholesterol and stimulates bile acid synthesis without cardiac effects in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-012-0300-X

CETP Inhibition: does the future look promising?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-012-0300-X

CETP inhibitors to increase HDL cholesterol levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-012-0300-X

Effects of torcetrapib in patients at high risk for coronary events

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-012-0300-X

Cholesteryl ester transfer protein inhibitor torcetrapib and off-target toxicity: a pooled analysis of the rating atherosclerotic disease change by imaging with a new CETP inhibitor (RADIANCE) trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-012-0300-X

Safety of anacetrapib in patients with or at high risk for coronary heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-012-0300-X

Rationale and design of the dal-OUTCOMES trial: efficacy and safety of dalcetrapib in patients with recent acute coronary syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-012-0300-X

Effects of the CETP inhibitor evacetrapib administered as monotherapy or in combination with statins on HDL and LDL cholesterol: a randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-012-0300-X

Design of the DEFINE trial: determining the EFficacy and tolerability of CETP INhibition with AnacEtrapib

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-012-0300-X

RVX-208: a small molecule that increases apolipoprotein A-I and high-density lipoprotein cholesterol in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-012-0300-X

Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report

21 January 2018

1 reference

12 December 2020

The seven countries study: 2,289 deaths in 15 years

1 reference

12 December 2020

The resurgence of thyromimetics as lipid-modifying agents.

1 reference

12 December 2020

Familial cholesteryl ester transfer protein deficiency is associated with triglyceride-rich low density lipoproteins containing cholesteryl esters of probable intracellular origin

1 reference

12 December 2020

Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy

1 reference

12 December 2020

An MTP inhibitor that normalizes atherogenic lipoprotein levels in WHHL rabbits

1 reference

12 December 2020

Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)

1 reference

12 December 2020

Plasma very low density lipoproteins contain a single molecule of apolipoprotein B

1 reference

12 December 2020

Regulation of the apolipoprotein B in heterozygous hypobetalipoproteinemic knock-out mice expressing truncated apoB, B81. Low production and enhanced clearance of apoB cause low levels of apoB

1 reference

12 December 2020

10.1007/S11883-012-0300-X

Identifiers

DOI

1 reference

PubMed ID

23307117

Dimensions Publication ID

28 August 2017

0 references

1 reference

PubMed ID

23307117